Abstract
Introduction
In Candida lusitaniae, mutations in FUR1 can be readily distinguished from mutations in FCY1 88 and FCY2 because only fur1 mutations result in cross-resistance to 5FU [8] . Likewise, in 89
Candida dubliniensis, natural missense fur1 mutations affect both 5FC and 5FU resistance [9] . 90 However, little work has been conducted on 5FC resistance directly in Cryptococcus. One of the 91 few early studies suggested that reductions in FUR1 activity may be linked to resistance to 5FC 92 based on a high frequency of cross-resistance to 5FU [10] . However, this study took place prior 93 to the cloning or sequencing of the FUR1 gene in Cryptococcus and attribution of resistance to 94 FUR1 was based only on cross-resistance to 5FU. More recent studies of 5FC resistant 95
Cryptococcus bacillisporus isolates found no mutations in FCY1, FUR1, or any of three putative 96 FCY2 paralogs that explained drug resistance [11] . 97
Recent work has demonstrated one source of increased rates of resistance to antifungal 98 drugs in Cryptococcus: defects in the DNA mismatch repair pathway [12, 13] . Natural isolates 99 with DNA mismatch repair defects have been identified in both an outbreak population of 100
Cryptococcus deuterogattii [12, 14] and in Cryptococcus neoformans [13, 15] . Defects in 101 mismatch repair are also common in other human fungal pathogens, including Candida glabrata 102 [16] . Depending on the population studied, multidrug resistance is sometimes linked to the 103 hypermutator state in C. glabrata [17, 18 ]. Here we demonstrate that DNA mismatch repair 104 defects also enable rapid resistance to 5FC in C. deuterogattii (previously known as C. gattii 105 VGII [19] [20] [21] ). We then utilize whole genome Illumina sequencing, in combination with 106 candidate-based Sanger sequencing, to identify the genetic basis for drug resistance in 10 107 independent isolates. We attribute resistance to mutations in FUR1 and unexpectedly, we also 108 identify a novel pathway of resistance to 5FC involving mutations in the pathway responsible for 109 producing the capsule, a core component of Cryptococcal virulence. 110
111

Results
112
In a previous study, we demonstrated that mismatch repair mutations conferred increased 113 rates of resistance to the antifungal drugs FK506 and rapamycin [12] . Because these 114 hypermutator strains are found among both environmental and clinical isolates, here we tested if 115 a hypermutator state could also confer resistance to one of the front-line drugs used to treat 116
Cryptococcosis: 5-fluorocytosine (5FC). A semi-quantitative swabbing assay was first employed 117 to demonstrate that deletions of the mismatch repair gene MSH2 in Cryptococcus deuterogattii 118 confer an elevated rate of resistance to 5FC ( Figure 1A ). This result was confirmed using a 119 quantitative fluctuation assay approach ( Figure 1B ). This assay revealed a greater than 15-fold 120 increase in the generation of resistance to 5FC in msh2Δ mismatch repair defective mutants. 121
Similarly, a simple spreading assay using VGIIa-like strains that had previously been found to 122
harbor an msh2 nonsense allele [12] demonstrated a much higher rate of resistance to both 5FC 123 and 5FU than in the VGIIa non-hypermutator strains (Supplemental Figure 1) . 124
In previous studies, mutator alleles in C. deuterogattii were not found to be generally 125 advantageous in rich media [12] . However, under stressful conditions, such as drug challenge 126 with FK506 and rapamycin, mutator alleles were highly beneficial. A competitive growth 127 experiment was utilized to test the same concept with 5FC. Mutator strains became resistant to 128 5FC at a higher rate and thus rapidly outcompeted wildtype strains (Figure 2 ). However, in the 129 absence of added stress, the mutator alleles showed no such advantage. This result suggests that 130 drug challenge during infection may select for strains with elevated mutation rates that are able 131 to acquire drug resistance more rapidly. 132
In other fungi, resistance to 5FC is typically mediated by mutations in one of three genes: 133 FCY1, FCY2, or FUR1 [7,8,10,22]. As described above, mutations in FCY1 and FCY2 are 134 typically distinguishable from fur1 mutations because mutations in FUR1 confer resistance not 135 only to 5FC but also to 5FU. In contrast, fcy1 and fcy2 mutations confer resistance to only 5FC. 136
To define the mechanism underlying 5FC resistance in C. deuterogattii, 29 resistant colonies 137 were isolated and tested, originating from the wildtype (R265, 9 colonies) and from two 138 independent msh2Δ mutants derived in the R265 background (RBB17, 10 colonies and RBB18, 139 10 colonies). Cultures were started from independent colonies and a single resistant colony was 140 selected from each culture, so that only one resistant isolate is derived from any original colony 141 derived from the frozen stock. All of the 5FC resistant isolates (Table 1) However, when the FUR1 gene was sequenced in this set of 5FC/5FU resistant isolates, 145 unexpectedly, only three out of 29 isolates (10.3%) were found to have sustained mutations in 146 FUR1 (R265-3, R265-4, and R265-6) ( Table 1) . Because fur1 mutations were the only known 147 cause of 5FC/5FU cross-resistance, we performed whole genome Illumina sequencing on a 148 subset of the remaining isolates to identify unknown genes underlying resistance. We sequenced 149 3 additional R265 isolates, 8 additional RBB17 isolates, and 9 additional RBB18 isolates, for a 150 total of 20 5FC and 5FU resistant isolates. 151
From the sequenced genomes, reads were aligned to the R265 reference genome and 152
SNPs and indels were identified. This analysis revealed that some of the presumed independent 153 isolates were in fact siblings. Four groups of siblings existed (RBB17-3 and RBB17-4; RBB17-5 154 and RBB17-8; RBB18-2, RBB18-4, and RBB18-5; RBB18-6 and RBB18-9), resulting in a total 155 of 3 independent R265 genomes, 6 independent RBB17 genomes, and 6 independent RBB18 156 genomes.
Of these 15 independent genome sequences, two contained unambiguous mutations in 158 FUR1. One strain (R265-2), for which PCR amplification of the FUR1 locus had failed, showed 159 an approximately 20 kb deletion. One end of the deletion lies within FUR1, consistent with the 160 failed PCR. The other end of the deletion fell within a sequencing gap of the annotated V2 R265 161 reference genome. To identify the precise location of this second breakpoint, reads from R265-2 162 were mapped to a recent Nanopore and Illumina hybrid assembly of the R265 strain [23] . 163
Interestingly, the second breakpoint was found within a gene encoding a weak paralog of FUR1 164 (5 x 10 -10 protein BLAST e-value). This paralog (CNBG_4055) is also present in C. neoformans 165 (CNAG_2344), suggesting that if it arose via duplication, it was before the last common ancestor 166 to both species. Given that deletion of FUR1 confers resistance to 5FC and 5FU, it is unlikely 167 that this paralog performs the same function as Fur1 ( Figure 3A ). Despite the protein similarity, 168 no obvious nucleotide homology was found that may have mediated this large deletion 169 conferring 5FC resistance. In fact, the FUR1 paralog is inverted relative to FUR1, reducing the 170 likelihood that remnant homology may have generated a region susceptible to frequent 171 homology-mediated deletion of FUR1 that would yield the type of regional deletion observed 172
here. 173
The second fur1 mutation discovered by whole genome sequencing was a single base 174 deletion that introduced a frameshift (R265-1) that had not initially been detected via Sanger 175 sequencing. A Gly190Asp fur1 missense mutation was also identified in the msh2 mutant 176 background (RBB17-5 and RBB17-8 sibling pair) (Table 1) . However, this mutation was present 177 in the sequencing of each strain at approximately 50% frequency, which would typically suggest 178 a heterozygous variant. Because the starting strains used were haploid, and there was no 179 indication of local duplication or any other indication of heterozygous variants in the genomes of 180 these strains, it seems unlikely that these data are indicative of a heterozygous mutation. One 181 alternate explanation is that the strains sequenced were mixed cultures or that the fur1 mutation 182 reverted during the expansion of the culture for whole genome sequencing, which was not 183 performed under selection. A test of individual colonies from the frozen culture of both sibling 184 strains showed that 10 out of 10 colonies from each strain demonstrated both 5FC and 5FU 185 resistance, suggesting that these strains were either a mixed culture of two different mutations 186 that both confer resistance to 5FU and 5FC, or that fur1 mutations were lost during outgrowth for 187 sequencing (Supplemental Figure 2) . 188 A Trp167STOP mutation in FCY2 (CNBG_3227) was also detected in the sequenced set 189 (RBB18-2, RBB18-4, and RBB18-5 sibling strains). While one of these mutations was nearly 190 unambiguous (84% alternate allele, RBB18-4), RBB18-2 and RBB18-5 exhibited more mixed 191 sequence at this locus. When individual colonies were isolated and retested from RBB18-2 and 192 RBB18-5, they all showed resistance to both 5FC and 5FU (Supplemental Figure 2) . Mutations 193 in FCY2 were particularly unexpected because in other fungi they do not confer resistance to 194 5FU and because there are 2 additional paralogs of FCY2 present in the Cryptococcus genome. 195 We attempted to test the ortholog of FCY2 from Cryptococcus neoformans using a deletion 196 collection strain but found that the mutant in the collection retained a functional FCY2 allele. It is 197 possible that this mutation may be a false positive, especially because all three of these sibling 198 strains contained a second mutation in a gene that also plays a role in 5FC and 5FU resistance 199
In total, out of 29 original 5FC resistant strains (Table 1) , six independent fur1 mutations 201 were identified using Sanger and Illumina sequencing. One independent fcy2 mutation was 202 identified by Illumina sequencing. We did not identify any fcy1 mutations, although fcy1 203 mutations confer resistance to 5FC in Cryptococcus neoformans (Supplemental Figure 3) . In 204 total, 13 sequenced genomes representing 11 independent isolates remained with no mutations in 205 any genes known to have a role in 5FC or 5FU resistance. These genomes were examined to 206 identify novel candidate mutations. To distinguish causal variants from background mutations, 207 candidate genes were required to be mutated in at least two different independent isolates. 208
Variant impact was also scored using SNPeff [24] and mutations were not considered if 209 predicted to have low impact (i.e., synonymous, intronic, or non-coding variants). Mutations of 210 moderate or higher impact were identified at a total of 56 sites (Supplemental Table 3 ). To 211 further prioritize, we specifically focused on mutations that were present in isolates from more 212 than one of the parental backgrounds. We identified UXS1, which sustained four novel mutations 213 in seven isolates from two parental backgrounds ( Figure 3B ). 214 UXS1 encodes the enzyme that converts UDP-glucuronic acid to UDP-xylose [25] . This 215 pathway is critical for the formation of the capsule, a core virulence trait of Cryptococcus, and 216 for synthesis of other glycoconjugates. There is no UXS1 ortholog in either Saccharomyces 217 cerevisiae or Candida albicans, where many of the resistance mechanisms for 5FC were 218 elucidated. The mutations in UXS1 included a single base deletion in a 3 T homopolymer (R265-219 5), a single base insertion in a 7 C homopolymer (RBB18-8), and a missense mutation 220 (Tyr217Cys, RBB18-6 and RBB18-9 sibling pair) that, like some of the previously identified 221 FUR1 mutations, displayed mixed sequences at the mutation site ( Figure 3B , Table 1 ). Finally, a 222 uxs1 mutation (Asp306Gly) was identified in the three sibling isolates that also had fcy2 223 mutations (RBB18-2, RBB18-4, and RBB18-5 siblings). Both the uxs1 and fcy2 mutations were 224 not present in 100% of the reads. However, both mutant alleles had allele frequencies >50%, 225 suggesting the genome sequence was not just a mix of a uxs1 mutant strain and an fcy2 mutant 226 strain, but instead that both mutations were present in at least a portion of the cells in the culture. 227
Among the sequenced isolates, mixed allele frequencies appeared only in the hypermutator 228 strains, suggesting that the rapid rate of mutation in these isolates may have contributed to 229 difficulties acquiring or maintaining a clonal population during the expansion of cultures used to 230 prepare DNA for whole genome sequencing, although more hypermutator strains were 231 sequenced than wildtype strains. In sum, 9 sequenced genomes representing 8 independent 232
isolates remained for which we were unable to identify a mutation that conferred resistance to 233 5FC and 5FU, all derived from msh2 mutant isolates. 234
To confirm the role of uxs1 mutation in resistance to 5FC and 5FU, a uxs1 deletion 235 available from a C. neoformans deletion collection was employed ( Figure 4A ). This uxs1Δ strain 236 was completely resistant to both drugs, suggesting that all three alleles isolated were likely loss 237 of function mutations because they shared a drug resistance phenotype with the null mutant. We 238 next sought to genetically define the mechanism by which drug resistance may be mediated by 239 loss of uxs1 function. Multiple models were considered to explain why 5FC/5FU toxicity would 240 require Uxs1. The first was that Uxs1 directly converts 5FU into a toxic product. If so, Uxs1 and 241
Fur1 would function in the same pathway, as either mutant independently confers drug 242
resistance. This hypothesis was tested using an overexpression allele of UXS1 that is driven by 243 the actin promoter [26] . If this hypothesis were correct, we would expect to observe additional 244 sensitivity conferred by the overexpression allele compared to wildtype. By reducing the amount 245 of 5FU used to only 1 µg/mL, wildtype strains were only partially inhibited. However, 246 introduction of an overexpression allele of UXS1 did not increase sensitivity ( Figure 4B ). This 247 suggests that Uxs1 does not act by converting 5FU or a 5FU derivative into a toxic product. 248
We next tested whether 5FC resistance in uxs1 mutants may occur through an indirect 249 effect of the role of Uxs1 in synthesis of UDP-xylose. UDP-xylose is the donor molecule for 250 xylose addition to glycans, a process that primarily occurs in the secretory compartment. If 251 xylosylation of an unknown glycoconjugate is required to mediate 5FC toxicity, mutation of 252 UXS1 would indirectly confer drug resistance. To test this, deletion mutants lacking transporters 253 that move UDP-xylose into the secretory compartment (uxt1, uxt2, and a uxt1 uxt2 double mutant 254
[27]) or that lack Golgi xylosyl-transferases that act in protein, glycolipid, and polysaccharide 255 synthesis (cxt1 [28] , cxt2, and a cxt1 cxt2 double mutant) were analyzed. None of these mutants 256 demonstrated any change in sensitivity to 5FC or 5FU ( Figure 4C ). However, these data did not 257 rule out a requirement for a (previously undescribed) cytoplasmic xylosyl protein modification. 258
To test this hypothesis, a mutant that cannot generate UDP-glucuronic acid, the immediate 259 precursor for UDP-xylose synthesis was used. This mutant (ugd1) is somewhat growth impaired 260 relative to wildtype and cannot grow on YNB media. However, it does grow, albeit poorly, on 261 rich YPD media, where it clearly exhibited sensitivity to 5FC. This result demonstrated that 262 xylose modification, in any cellular compartment, is not required for 5FC toxicity ( Figure 4D ). 263
The previous models ruled out the lack of UDP-xylose for synthetic processes as an 264 explanation for 5FC resistance. Another result of the loss of UXS1 function is the accumulation 265 of UDP-glucuronic acid, the immediate precursor in the production of UDP-xylose. Past studies 266 have shown that UDP-glucuronic acid accumulates to extremely high levels in uxs1 mutant cells 267 [29] . To test whether this mediates resistance, we generated a uxs1 ugd1 double mutant, which 268 should produce neither compound [29] . While the uxs1 ugd1 mutant was growth impaired, like 269 the ugd1 single mutant, it was clearly sensitive to 5FC ( Figure 4D ). That uxs1 mutants are 5FC 270 resistant, whereas uxs1 ugd1 double mutants are restored to 5FC sensitivity suggests that 271 accumulation of UDP-glucuronic acid in uxs1 mutants mediates resistance to 5FC and 5FU 272 Previous work showed this type of direct reversion of an auxotrophic ade2 mutation [12] . 293
We explored the underlying genetic and genomic basis of 5FC resistance. The resistant 294 mutants in C. deuterogattii selected here were cross-resistant to 5FU. Sanger and whole genome 295
Illumina sequencing identified a presumptive genetic basis for drug resistance in 10 independent 296
isolates. Analysis of resistance loci was relatively facile in wildtype strains, where an average of 297 1.66 coding mutations were identified by whole genome sequencing, including the putative 298 resistance mutation, relative to the reference. However, this analysis was substantially more 299 difficult in mutator strains where an average of 7.9 coding mutations were found per strain, with 300 numerous additional noncoding or synonymous mutations. In addition, the phenomenon of 301 mixed allele ratios in sequencing data was only observed in hypermutator strains. Likewise, 302 sibling strains emerged from the selection, despite use of standard genetic best practices for 303 isolating independent resistant mutants. This suggests that the initial freezer stock from each 304 hypermutator strain had substantial existing mutations and population structure, which is not 305 typically an issue for frozen Cryptococcus cultures. For the purposes of identifying the genetic 306 basis of a trait that occurs at a high rate in wildtype, future studies would be advised to avoid 307 mutations that increase mutation rate, as they contribute to background noise. 308
Mutations in UXS1 are particularly interesting as a mechanism of resistance in 309
Cryptococcus because Uxs1 catalyzes the production of UDP-xylose, the donor molecule for 310 essential components of Cryptococcal capsule polysaccharides. Strains lacking UXS1 are 311 hypocapsular with altered capsule structure [29] . In addition, uxs1 mutants are avirulent in a 312 murine tail-vein injection disseminated infection model [32] . This suggests that uxs1 mutants 313 might be unlikely to emerge during exposure to 5FC in vivo, even though they represent a 314 substantial proportion of the resistant isolates observed in this study. Future studies examining 315 the mechanisms of resistance during treatment with 5FC in vivo will provide further insights into 316 the possible contribution of uxs1 mutations to resistance in patients. 317
This study also illustrates the importance of examining drug resistance in the context of 318 the pathogen being treated. Previous work in C. albicans and S. cerevisiae suggested that 319 resistance would occur through mutations in FUR1, but both species are evolutionarily distant 320
from Cryptococcus and lack a UXS1 ortholog. While these previous studies provided substantial 321 insight into 5FC toxicity, studies in the pathogen of interest are essential. Surprisingly, one set of 322 sibling strains (RBB18-2, RBB18-4, RBB18-5) that were cross resistant to 5FU had mutations in 323 the FCY2 gene (CNBG_3227), which in other species confers resistance to 5FC but not 5FU. 324
Unexpected cross-resistance between 5FC and fluconazole has been previously observed in fcy2 325 mutants of Candida lusitaniae but is proposed to occur through competitive inhibition of 326 fluconazole uptake by 5FC that can no longer enter through Fcy2-mediated transport [8, 33, 34] . 327 C. lusitaniae fcy2 mutants are not resistant to fluconazole without the addition of 5FC. In 328 addition, multiple resistant strains were not assigned a presumptive causative mutation here and 329 lacked mutations in any genes known to cause 5FC resistance from this or previous work (FUR1, 330 FCY1, FCY2, and UXS1). Presumably unknown mechanisms are responsible for resistance to 331 5FC and 5FU in these strains as well, either in pathways unique to Cryptococcus or potentially 332 more broadly conserved. 333
In addition, UXS1 mutations provide unexpected insight into interaction between 334 nucleotide synthesis and generation of precursors for xylosylation. Surprisingly, accumulation of 335 UDP-glucuronic acid appears to either inhibit the pyrimidine salvage pathway or activate 336 thymidylate synthase ( Figure 5 ). This suggests that UDP-glucuronic acid may have a role as a 337 source of UDP for the cell, while UDP-xylose does not. While UXS1 orthologs are not found in 338 C. albicans or S. cerevisiae, which lack xylose modifications, there is a UXS1 ortholog in 339 humans. 5FU is commonly used as a chemotherapeutic drug [35] , and resistance to 5FU is 340 frequently associated with mutations in thymidylate synthase [36] . Data here suggest that uxs1 341 mutations may be acting in a similar fashion to either de-repress thymidylate synthase or inhibit 342 
Material and methods
346
Strains and media 347
The strains and plasmids used in this study are listed in Table S1 . The strains were 348 maintained in glycerol stocks at -80°C and grown on rich YPD media at 30°C (Yeast extract 349 Peptone Dextrose). Strains with selectable markers were grown on YPD containing 100 µg/mL 350 nourseothricin (NAT) and/or 200 µg/mL G418 (NEO 
Spot dilution assays 393
Single colonies were inoculated into 5 mL of liquid YPD and grown overnight at 30°C. 394
Cell density was determined using a hemocytometer and the cultures were diluted accordingly 395 such that 100,000 cells were aliquoted on to the most concentrated spot and subsequent spots 396 consisted of 10-fold dilutions per spot. Each strain was spotted onto YPD or YNB alone and onto 397 media also containing 5FC or 5FU at the indicated concentration. Plates were incubated at 30°C 398 until photographed. 399 400
Swab assays 401
Swab assays were conducted as previously described [12] . Briefly, independent colonies 402 were inoculated in liquid YPD media and cultured with shaking until saturation. mechanism. 578 A) KN99 deletion strains from the C. neoformans deletion collection show that deletion of UXS1 579 confers resistance to 5FC and 5FU. The RBB18-2 strain carrying an fcy2 and uxs1 mutation is 580 resistant to 5FC and 5FU although more weakly to 5FU. The R265-3 strain carrying a fur1 581 mutation is completely resistant to both drugs. B) Spot dilution assay on YNB, YNB plus 5FC, 582 and YNB plus 5FU demonstrating overexpression of UXS1 driven by the actin promoter does not 583 confer increased sensitivity to 5FC or 5FU. C) Spot dilution assays on YNB, YNB plus 5FC, and 584 YNB plus 5FU demonstrating that mutants deficient in UDP-xylose transport (uxt1Δ, uxt2Δ, 585 uxt1Δ uxt2Δ) and xylose transferase mutants (cxt1Δ, cxt2Δ, cxt1Δ cxt2Δ) show no change in 5FC 586 and 5FU sensitivity. D) Spot dilution assay on YPD, YPD plus 5FC, and YPD plus 5FU showing 587 that ugd1 mutants are viable on rich YPD media but retain sensitivity to 5FC and 5FU. In 588 addition, ugd1 uxs1 double mutants retain sensitivity to 5FC and 5FU like a ugd1 single mutant 589 rather than gain resistance like the uxs1 single mutant. 590 fur1Δ and fcy1Δ strains from the KN99 C. neoformans collection were struck onto YNB, YNB + 618 100 µg/mL 5FC, and YNB + 100 µg/mL 5FU. While the fcy1Δ mutant strain grew on media 619 containing 5FC, it did not grow on media containing 5FU. In contrast, the fur1Δ mutant strain 620 grew on media with either drug. 621 622 
